CDK4/6 INHIBITOR
Clinical trials for CDK4/6 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new CDK4/6 INHIBITOR trials appear
Sign up with your email to follow new studies for CDK4/6 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Brand or generic? new study tests palbociclib in advanced breast cancer
Disease control OngoingThis study compares the effectiveness and safety of branded palbociclib (Ibrance) versus a local generic version in 100 Iraqi women with advanced hormone receptor-positive, HER2-negative breast cancer. The main goal is to see how long the cancer stays under control (progression-f…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: Al-Mustansiriyah University • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New study aims to predict dangerous side effects of common breast cancer drugs
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 100 breast cancer patients taking CDK4/6 inhibitor drugs. Researchers want to find genetic and blood markers that can predict who will have bad side effects or not get enough benefit from the medication. The goal is to help doctors choose safer and more effect…
Matched conditions: CDK4/6 INHIBITOR
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:09 UTC